GOSS Stock Summary and Trading Ideas (Gossamer Bio | NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Gossamer Bio trades on the NASDAQ stock market under the symbol GOSS.

As of September 11, 2026, GOSS stock price declined to $10.73 with 467,464 million shares trading.

GOSS has a beta of 3.29, meaning it tends to be more sensitive to market movements. GOSS has a correlation of 0.05 to the broad based SPY ETF.

GOSS has a market cap of $5.25 billion. This is considered a Mid Cap stock.

Last quarter Gossamer Bio reported $9 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.04.

In the last 3 years, GOSS traded as high as $309.60 and as low as $9.10.

The top ETF exchange traded funds that GOSS belongs to (by Net Assets): VTI, VXF, SCHA, VHT, ESSC.

GOSS has underperformed the market in the last year with a price return of -96.1% while the SPY ETF gained +17.4%. GOSS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.4% and -21.1%, respectively, while the SPY returned +3.9% and -0.7%, respectively.

GOSS support price is $10.42 and resistance is $12.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GOSS shares will trade within this expected range on the day.